Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
38.2M
-
Shares change
-
+5.71M
-
Total reported value, excl. options
-
$641M
-
Value change
-
+$95.8M
-
Put/Call ratio
-
1.02
-
Number of buys
-
28
-
Number of sells
-
-1
-
Price
-
$16.78
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2024
120 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q2 2024.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.2M shares
of 46.2M outstanding shares and own 82.67% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.56M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.3M shares), RA CAPITAL MANAGEMENT, L.P. (3.08M shares), GREAT POINT PARTNERS LLC (2.91M shares), Point72 Asset Management, L.P. (2.45M shares), MENORA MIVTACHIM HOLDINGS LTD. (2.3M shares), BlackRock Inc. (2.19M shares), COWEN AND COMPANY, LLC (2.1M shares), MORGAN STANLEY (1.84M shares), and Cormorant Asset Management, LP (1.65M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.